<DOC>
	<DOCNO>NCT01328821</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics CTP-499 follow single dose administration .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ( PK ) CTP-499</brief_title>
	<detailed_description>This double-blind , single ascend dose administration study four dos CTP-499 . Following dose safety tolerability assess . Blood urine sample take pharmacokinetics ( PK ) bioavailability . Safety assessment include monitor adverse event , vital sign ( blood pressure , pulse rate , respiratory rate oral temperature ) , clinical laboratory finding , 12-lead ECGs , physical examination finding . The plasma concentration time data CTP-499 metabolite analyze use noncompartmental method . Actual dosing sample time use analysis . The primary pharmacokinetics parameter : Cmax , Tmax , T1/2 , AUClast AUCinf plasma ; relative bioavailability ; Ae CLr urine .</detailed_description>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>healthy volunteer age 18 55 year old nonsmoker BMI 18 30 kg/m2 Significant history gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematologic , psychiatric , renal , hepatic , bronchopulmonary , neurologic , immunologic , lipid metabolism disorder drug hypersensitivity Systolic Blood pressure &lt; 90 &gt; 140 , diastolic bp &gt; 90</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>